enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Eli Lilly Alzheimer's drug approved by US FDA - AOL

    www.aol.com/news/us-fda-approves-lillys...

    The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency's outside experts, who unanimously backed its use in patients with early Alzheimer's ...

  3. FDA approves Alzheimer’s treatment that has been shown to ...

    www.aol.com/news/fda-approves-alzheimer...

    (Eli Lilly) The agency’s approval was based on a late-stage clinical trial of 1,700 people that showed the drug slowed the progression of Alzheimer’s by about 35% after 18 months, compared to ...

  4. A New Alzheimer’s Drug May Be the Most Effective One Yet - AOL

    www.aol.com/alzheimer-drug-may-most-effective...

    Lilly Biotechnology Center in San Diego, Calif. Credit - Getty Images. O n July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or ...

  5. Lilly Alzheimer's drug gets unanimous backing from FDA ... - AOL

    www.aol.com/news/us-fda-advisers-review-eli...

    (Reuters) -Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's experimental Alzheimer's treatment donanemab outweighed its risks ...

  6. Second Alzheimer's drug in pipeline can slow the ... - AOL

    www.aol.com/news/second-alzheimers-drug-pipeline...

    Lilly’s study enrolled people ages 60 to 85 who were in early stages of Alzheimer’s. Half received once-a-month infusions of donanemab and half dummy infusions for 18 months. The study had a ...

  7. Donanemab – what we know about the latest Alzheimer’s drug

    www.aol.com/donanemab-know-latest-alzheimer-drug...

    Donanemab is given to patients via an intravenous drip once every four weeks. Lilly has said that some patients can complete their course of treatment in as little as six months once their amyloid ...

  8. FDA approves donanemab, Eli Lilly’s treatment for early ...

    www.aol.com/fda-approves-donanemab-eli-lilly...

    Lilly told a committee of FDA advisers in June that late-stage clinical research data showed “highly meaningful results” for people who took donanemab, with about 35% lower risk of progression ...

  9. Eli Lilly and Co. Executive Vice President Anne White said in a statement that the Indianapolis-based company remains confident in donanemab’s potential and will work with the FDA.